Ipsen : Etude CheckMate9ER Cabometyx+Opdivo : données prometteuses – OC relevé: 100 € vs 91 €
>Des données d’efficacité et de survie, intéressantes - Lors du congrès ESMO (European Society for Medical Oncology), Ipsen a annoncé les résultats de son étude pivotale de Phase III CheckMate 9ER dans laquelle Cabometyx® (cabozantinib) en combinaison avec Opdivo® (nivolumab) de BMS, démontrant des améliorations significatives sur tous les critères d’efficacité (en particulier la survie globale), chez des patients atteints d’un carcinome du rein avancé (RCC) non trait...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.